(CDAX, Technology, BSL GR)



| Hold | | Valu |
|-------------------|-------------|------|
| iioiu | | DCF |
| EUR 115.00 | (EUR 76.00) | FCF |
| | | Mar |
| Price | EUR 112.00 | Marl |
| l locido | | No. |
| Upside | 2.7 % | EV: |
| | | Free |

| Value Indicators: | EUR | Warburg ESG Risk Score: | 2.7 | Description: | |
|--------------------------|-----------|-------------------------|--------|-------------------------------|-----------|
| DCF: | 114.98 | ESG Score (MSCI based): | 3.0 | B2B digital cameras for app | lications |
| FCF-Value Potential 23e: | 65.97 | Balance Sheet Score: | 4.0 | such as factory, medical, tra | affic or |
| | | Market Liquidity Score: | 1.0 | retail. | |
| Market Snapshot: | EUR m | Shareholders: | | Key Figures (WRe): | 2021e |
| Market cap: | 1,113.5 | Freefloat | 39.0 % | Beta: | 1.1 |
| No. of shares (m): | 9.9 | Norbert Basler | 52.0 % | Price / Book: | 8.3 x |
| EV: | 1,103.0 | Treasury shares | 5.0 % | Equity Ratio: | 75 % |
| Freefloat MC: | 434.3 | Dr. Ley (CEO) | 4.0 % | | |
| Ø Trad. Vol. (30d): | 435.02 th | | | | |

Estimates and target price increased after strong Q1

| Stated Figure | es Q1/2 | 021: | | | | | |
|----------------------------|-------------------------|-------------------------|-------------------------|--------------|---------------|--------------------------|--------------|
| FY End: 31.12. in EUR m | Q1 21 | Q1 21e | Q1 20 | yoy | 21e | 20 | yoy |
| Sales EBIT | 54.6 10.1 | 54.6 10.0 | 43.7 6.4 | 25 % 57 % | 224.8 35.7 | 170.5 20.1 | 32 % 78 % |
| Margin EBT Margin | 18.4 % 9.9 18.2 % | 18.2 % 9.9 18.1 % | 14.7 % 6.3 14.3 % | 59 % | 34.9 | 11.8 % 20.4 12.0 % | 71 % |

Comment on Figures:

- Significant top-line growth should have been driven by demand from the semi- and electronics industry in response to the current chip shortage
- Profitability improved significantly as a result of higher revenues
- We also expect a strong gross margin driven by a favourable product mix and a low share of revenues from less profitable large orders

Basler has reported strong figures for the first quarter and increased the outlook for the full year. Sales grew by 25% to EUR 54.6m and the order intake increased by 27% to EUR 67.3m. This was mainly driven by high investment in the semi- and electronics industry in response to the current chip shortage. The EBT margin increased from 14.3% to 18.2% as a result of a gross margin improvement of 2.2pp. Against this background, Basler increased its sales guidance from EUR 190-210m to EUR 205-225m and the EBT margin target from 12-14% to 13-15.5%. We have increased our short-term and mid-term estimates significantly and expect the higher growth to be driven by:

- Chip shortage: While the semi capex cycle usually consists of one to two years of growth followed by a downturn of roughly the same duration, the current chip shortage and the increasing demand from the automotive industry should lead to a longer period of growth. The industry association, SEMI, forecasts that semi capex will increase by 15.5% this year and 12% next year.
- Factory automation recovery: Demand from general industry has been rather low for two years now and we expect some recovery once the pandemic has ended starting in H2.
- Cross-selling: Basler has expanded its portfolio to become a full-range supplier, offering cables, lenses, lighting and frame grabber in addition to the camera. In a next step, Basler will bundle those products to solutions and gain a larger share of its customers' wallet.


After the strong Q1 figures, we have revised our model and increased our target price significantly to EUR 115. The higher valuation, however, seems to be already reflected in the current share price. Thus, we confirm our Hold recommendation.

| Changes in E | Estimates: | | | | | |
|----------------------------|----------------|--------|----------------|--------|----------------|------|
| FY End: 31.12. in EUR m | 2021e (old) | + / - | 2022e (old) | +/- | 2023e (old) | +/- |
| Sales | 202.3 | 11.1 % | 228.1 | 12.8 % | n.a. | n.m. |
| EBIT | 27.7 | 29.1 % | 33.7 | 19.1 % | n.a. | n.m. |
| EBT | 26.9 | 29.9 % | 32.9 | 19.6 % | n.a. | n.m. |
| EPS | 1.96 | 30.1 % | 2.37 | 19.8 % | n.a. | n.m. |

Q3

Comment on Changes:

- 2021 estimates increased in accordance with the updated guidance
- Higher growth forecast for 2022 driven by anticipation of higher demand from the semi and electronics industry and ongoing recovery in the factory automation business
- Beyond 2022 we expect Basler to increase its share of customer-wallet




Rel. Performance vs CDAX: 1 month: 13.1 % 6 months: 78.2 % Year to date: 47.4 % Trailing 12 months: 90.5 % Company events: 19.05.21 AGM 05.08.21 Q2

| FY End: 31.12. | CAGR | | | | | | | |
|---------------------|--------------|-------------|---------------|----------|--------|--------|--------|--------|
| in EUR m | (20-23e) | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Sales | 19.7 % | 150.2 | 150.0 | 162.0 | 170.5 | 224.8 | 257.3 | 292.4 |
| Change Sales yoy | | 54.0 % | -0.1 % | 8.0 % | 5.2 % | 31.9 % | 14.5 % | 13.6 % |
| Gross profit margin | | 49.6 % | 53.3 % | 50.9 % | 52.0 % | 52.4 % | 50.6 % | 49.8 % |
| EBITDA | 23.7 % | 39.7 | 36.0 | 30.0 | 34.6 | 54.9 | 60.2 | 65.5 |
| Margin | | 26.4 % | 24.0 % | 18.5 % | 20.3 % | 24.4 % | 23.4 % | 22.4 % |
| EBIT | 30.9 % | 30.5 | 24.8 | 17.0 | 20.1 | 35.7 | 40.2 | 45.0 |
| Margin | | 20.3 % | 16.6 % | 10.5 % | 11.8 % | 15.9 % | 15.6 % | 15.4 % |
| Net income | 28.2 % | 21.6 | 17.0 | 12.9 | 15.1 | 25.5 | 28.4 | 31.8 |
| EPS | 28.2 % | 2.25 | 1.76 | 1.29 | 1.51 | 2.55 | 2.84 | 3.18 |
| DPS | 18.0 % | 0.67 | 0.53 | 0.26 | 0.58 | 0.77 | 0.85 | 0.95 |
| Dividend Yield | | 1.6 % | 0.9 % | 0.6 % | 1.1 % | 0.7 % | 0.8 % | 0.9 % |
| FCFPS | | 2.46 | 0.93 | -0.97 | 1.38 | 1.60 | 2.11 | 2.13 |
| FCF / Market cap | | 5.8 % | 1.6 % | -2.1 % | 2.6 % | 1.4 % | 1.9 % | 1.9 % |
| EV / Sales | | 2.7 x | 3.8 x | 3.0 x | 3.2 x | 4.9 x | 4.3 x | 3.7 x |
| EV / EBITDA | | 10.2 x | 15.7 x | 16.1 x | 15.6 x | 20.2 x | 18.2 x | 16.5 x |
| EV / EBIT | | 13.2 x | 22.8 x | 28.4 x | 26.9 x | 31.1 x | 27.3 x | 24.1 x |
| P/E | | 18.8 x | 32.7 x | 36.4 x | 35.8 x | 43.9 x | 39.4 x | 35.2 x |
| P / E adj. | | 18.8 x | 32.7 x | 36.4 x | 37.0 x | 43.9 x | 39.4 x | 35.2 x |
| FCF Potential Yield | | 7.2 % | 4.1 % | 2.3 % | 4.8 % | 3.5 % | 3.8 % | 4.1 % |
| ROE | | 37.4 % | 24.1 % | 14.4 % | 13.9 % | 20.4 % | 19.5 % | 19.0 % |
| ROCE (NOPAT) | | 38.4 % | 23.8 % | 12.7 % | 12.8 % | 21.9 % | 22.5 % | 23.5 % |
| Guidance: 2 | 021 sales EU | IR 190-210m | ı, EBT margir | า 12-14% | | | | |

Analyst

04.11.21






Company Background

- Basler is a provider of digital cameras for production, medical applications, traffic control or retail.
- Basler focuses on the mainstream and entry-level market segments.
- Customers are mainly OEMs. The customer base is well diversified and no single customer accounts for more than 10% of revenue. More than 60% of revenues are direct sales.

Competitive Quality

- In terms of units Basler is the world's largest developer and manufacturer of digital cameras in a fragmented, but consolidating, market for digital cameras for B2B-applications.
- High level of vision technology expertise: Basler has one of the largest developer pools in the sector and differentiates itself with camera software competence, which accounts for more than 50% of the value creation.
- State-of-the-art product portfolio: Basler is among the first movers in digital cameras based on GigE Vision and the USB3 Vision standard. It is also an early adopter of new sensor technology.
- High service and consulting quality through direct sales and Basler's network of specialised distributors.
- Basler is present in the most important markets for vision technology in South East Asia, Europe and the US.



Basler



| DCF model | | | | | | | | | | | | | | |
|-----------------------------|---------|-----------|----------|--------|--------|--------|--------|-----------|-----------|--------|--------|--------|--------|-------------|
| | Detaile | d forecas | t period | | | | 7 | ransition | al period | | | | | Term. Value |
| Figures in EUR m | 2021e | 2022e | 2023e | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e | 2032e | 2033e | |
| Sales | 224.8 | 257.3 | 292.4 | 330.1 | 378.6 | 432.6 | 492.5 | 558.5 | 631.2 | 710.9 | 798.0 | 892.8 | 998.8 | |
| Sales change | 31.9 % | 14.5 % | 13.6 % | 12.9 % | 14.7 % | 14.3 % | 13.8 % | 13.4 % | 13.0 % | 12.6 % | 12.2 % | 11.9 % | 11.9 % | 2.0 % |
| EBIT | 35.7 | 40.2 | 45.0 | 50.2 | 54.9 | 62.7 | 71.4 | 81.0 | 91.5 | 103.1 | 115.7 | 129.4 | 144.8 | |
| EBIT-margin | 15.9 % | 15.6 % | 15.4 % | 15.2 % | 14.5 % | 14.5 % | 14.5 % | 14.5 % | 14.5 % | 14.5 % | 14.5 % | 14.5 % | 14.5 % | |
| Tax rate (EBT) | 27.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | 28.0 % | |
| NOPAT | 26.1 | 28.9 | 32.4 | 36.1 | 39.5 | 45.2 | 51.4 | 58.3 | 65.9 | 74.2 | 83.3 | 93.2 | 104.3 | |
| Depreciation | 19.3 | 20.0 | 20.5 | 19.1 | 22.0 | 25.1 | 28.6 | 32.4 | 36.6 | 41.2 | 46.3 | 51.8 | 57.9 | |
| in % of Sales | 8.6 % | 7.8 % | 7.0 % | 5.8 % | 5.8 % | 5.8 % | 5.8 % | 5.8 % | 5.8 % | 5.8 % | 5.8 % | 5.8 % | 5.8 % | |
| Changes in provisions | 0.8 | 0.0 | 0.0 | 1.1 | 0.4 | 0.5 | 0.5 | 0.6 | 0.7 | 0.7 | 8.0 | 0.9 | 1.0 | |
| Change in Liquidity from | | | | | | | | | | | | | | |
| - Working Capital | 9.9 | 4.9 | 6.0 | 5.9 | 7.7 | 8.5 | 9.9 | 10.9 | 12.0 | 13.1 | 14.4 | 15.6 | 17.5 | |
| - Capex | 21.5 | 23.1 | 25.8 | 19.8 | 22.5 | 25.4 | 28.7 | 32.2 | 36.0 | 40.2 | 44.6 | 49.4 | 57.9 | |
| Capex in % of Sales | 9.6 % | 9.0 % | 8.8 % | 6.0 % | 5.9 % | 5.9 % | 5.8 % | 5.8 % | 5.7 % | 5.6 % | 5.6 % | 5.5 % | 5.8 % | |
| Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Free Cash Flow (WACC Model) | 14.8 | 20.9 | 21.1 | 30.6 | 31.7 | 36.8 | 42.0 | 48.2 | 55.2 | 62.9 | 71.4 | 80.8 | 87.7 | 100 |
| PV of FCF | 14.2 | 18.7 | 17.6 | 23.9 | 23.1 | 24.9 | 26.6 | 28.4 | 30.4 | 32.3 | 34.2 | 36.1 | 36.6 | 798 |
| share of PVs | | 4.41 % | | | | | | 25.89 | 9 % | | | | | 69.69 % |

| Model parameter | | | | Valuation (m) | | | |
|--------------------------|---------|---------------------|------|----------------------------|-------|-----------------------|--------|
| Derivation of WACC: | | Derivation of Beta: | | Present values 2033e | 347 | | |
| | | | | Terminal Value | 798 | | |
| Debt ratio | 10.00 % | Financial Strength | 1.10 | Financial liabilities | 45 | | |
| Cost of debt (after tax) | 2.1 % | Liquidity (share) | 1.30 | Pension liabilities | 1 | | |
| Market return | 7.00 % | Cyclicality | 1.30 | Hybrid capital | 0 | | |
| Risk free rate | 1.50 % | Transparency | 1.00 | Minority interest | 0 | | |
| | | Others | 1.00 | Market val. of investments | 0 | | |
| | | | | Liquidity | 45 | No. of shares (m) | 9.9 |
| WACC | 7.20 % | Beta | 1.14 | Equity Value | 1,143 | Value per share (EUR) | 114.98 |

| Sens | itivity Va | lue per Sh | are (EUR) |) | | | | | | | | | | | | | |
|------|------------|------------|-----------|--------|--------|--------|--------|--------|------|-------|------------|----------|---------|---------|---------|---------|---------|
| | | Terminal (| Growth | | | | | | | | Delta EBIT | Γ-margin | | | | | |
| Beta | WACC | 1.25 % | 1.50 % | 1.75 % | 2.00 % | 2.25 % | 2.50 % | 2.75 % | Beta | WACC | -1.5 pp | -1.0 pp | -0.5 pp | +0.0 pp | +0.5 pp | +1.0 pp | +1.5 pp |
| 1.34 | 8.2 % | 85.83 | 87.82 | 89.97 | 92.29 | 94.80 | 97.54 | 100.52 | 1.34 | 8.2 % | 81.54 | 85.12 | 88.70 | 92.29 | 95.87 | 99.45 | 103.04 |
| 1.24 | 7.7 % | 94.56 | 97.02 | 99.69 | 102.59 | 105.75 | 109.22 | 113.04 | 1.24 | 7.7 % | 90.68 | 94.65 | 98.62 | 102.59 | 106.55 | 110.52 | 114.49 |
| 1.19 | 7.5 % | 99.50 | 102.24 | 105.23 | 108.48 | 112.06 | 115.99 | 120.34 | 1.19 | 7.5 % | 95.92 | 100.11 | 104.30 | 108.48 | 112.67 | 116.86 | 121.05 |
| 1.14 | 7.2 % | 104.87 | 107.95 | 111.30 | 114.98 | 119.03 | 123.51 | 128.49 | 1.14 | 7.2 % | 101.69 | 106.12 | 110.55 | 114.98 | 119.41 | 123.84 | 128.27 |
| 1.09 | 7.0 % | 110.75 | 114.20 | 117.99 | 122.16 | 126.78 | 131.91 | 137.65 | 1.09 | 7.0 % | 108.07 | 112.77 | 117.47 | 122.16 | 126.86 | 131.55 | 136.25 |
| 1.04 | 6.7 % | 117.20 | 121.10 | 125.39 | 130.14 | 135.43 | 141.34 | 148.00 | 1.04 | 6.7 % | 115.16 | 120.16 | 125.15 | 130.14 | 135.14 | 140.13 | 145.12 |
| 0.94 | 6.2 % | 132.15 | 137.19 | 142.80 | 149.07 | 156.14 | 164.16 | 173.34 | 0.94 | 6.2 % | 131.99 | 137.68 | 143.38 | 149.07 | 154.77 | 160.46 | 166.16 |

- Financial liabilities are also related to the lease of the company building.
- The beta takes into consideration the low liquidity of the share.
- The structural growth of the vision technology market forms the basis of Basler's revenue increases.



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

| in EUR m | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
|---------------------------------------|------------|--------|--------|--------|---------|---------|---------|
| Net Income before minorities | 21.6 | 17.0 | 12.9 | 15.1 | 25.5 | 28.4 | 31.8 |
| + Depreciation + Amortisation | 9.2 | 11.1 | 12.9 | 14.5 | 19.3 | 20.0 | 20.5 |
| - Net Interest Income | -0.7 | -0.3 | -0.1 | 0.4 | -0.8 | -0.8 | -0.8 |
| - Maintenance Capex | 2.8 | 2.9 | 5.0 | 0.0 | 6.7 | 7.7 | 8.8 |
| + Other | 0.3 | -2.1 | -10.0 | -3.3 | 0.3 | 0.3 | 0.3 |
| = Free Cash Flow Potential | 29.0 | 23.4 | 10.9 | 26.0 | 39.1 | 41.7 | 44.7 |
| FCF Potential Yield (on market EV) | 7.2 % | 4.1 % | 2.3 % | 4.8 % | 3.5 % | 3.8 % | 4.1 % |
| WACC | 7.20 % | 7.20 % | 7.20 % | 7.20 % | 7.20 % | 7.20 % | 7.20 % |
| = Enterprise Value (EV) | 402.6 | 564.9 | 482.6 | 539.5 | 1,109.5 | 1,096.5 | 1,084.2 |
| = Fair Enterprise Value | 402.6 | 325.1 | 151.6 | 360.5 | 542.4 | 579.5 | 620.1 |
| - Net Debt (Cash) | -2.8 | -2.8 | -2.8 | -2.8 | -12.4 | -25.4 | -37.7 |
| - Pension Liabilities | 1.1 | 1.1 | 1.1 | 1.1 | 1.9 | 1.9 | 1.9 |
| - Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| - Market value of minorities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| + Market value of investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| = Fair Market Capitalisation | 404.4 | 326.9 | 153.3 | 362.2 | 552.9 | 603.1 | 655.9 |
| Number of shares, average | 9.6 | 9.6 | 9.9 | 10.0 | 10.0 | 10.0 | 10.0 |
| = Fair value per share (EUR) | 42.00 | 33.90 | 15.42 | 36.20 | 55.29 | 60.31 | 65.59 |
| premium (-) / discount (+) in % | | | | | -50.6 % | -46.2 % | -41.4 % |
| Sensitivity Fair value per Share (EUF | ₹) | | | | | | |
| 10.2 | 20 % 28.76 | 23.26 | 10.94 | 25.77 | 39.57 | 43.52 | 47.63 |
| 9.2 | 20 % 31.87 | 25.77 | 12.11 | 28.55 | 43.76 | 47.99 | 52.41 |
| 8.2 | 20 % 35.73 | 28.89 | 13.56 | 32.01 | 48.96 | 53.55 | 58.36 |
| WACC 7.2 | 20 % 40.67 | 32.88 | 15.42 | 36.43 | 55.61 | 60.66 | 65.97 |
| 6.2 | 20 % 47.20 | 38.15 | 17.88 | 42.28 | 64.41 | 70.05 | 76.02 |
| | 20 % 56.24 | 45.45 | 21.28 | 50.37 | 76.58 | 83.06 | 89.94 |
| 4.2 | 20 % 69.58 | 56.22 | 26.30 | 62.31 | 94.55 | 102.26 | 110.48 |

Adjustment of the capitalised R&D impact

[•] The capex requirements for machinery and plant are low.

Basler



| Valuation | | | | | | | |
|-------------------------------------|--------|--------|--------|--------|--------|--------|--------|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Price / Book | 6.2 x | 7.4 x | 4.5 x | 4.7 x | 8.3 x | 7.2 x | 6.2 x |
| Book value per share ex intangibles | 4.22 | 3.57 | 4.10 | 5.00 | 6.66 | 8.32 | 10.08 |
| EV / Sales | 2.7 x | 3.8 x | 3.0 x | 3.2 x | 4.9 x | 4.3 x | 3.7 x |
| EV / EBITDA | 10.2 x | 15.7 x | 16.1 x | 15.6 x | 20.2 x | 18.2 x | 16.5 x |
| EV / EBIT | 13.2 x | 22.8 x | 28.4 x | 26.9 x | 31.1 x | 27.3 x | 24.1 x |
| EV / EBIT adj.* | 13.2 x | 22.8 x | 28.4 x | 26.9 x | 31.1 x | 27.3 x | 24.1 x |
| P/FCF | 17.2 x | 61.9 x | n.a. | 39.1 x | 73.7 x | 55.7 x | 55.2 x |
| P/E | 18.8 x | 32.7 x | 36.4 x | 35.8 x | 43.9 x | 39.4 x | 35.2 x |
| P / E adj.* | 18.8 x | 32.7 x | 36.4 x | 37.0 x | 43.9 x | 39.4 x | 35.2 x |
| Dividend Yield | 1.6 % | 0.9 % | 0.6 % | 1.1 % | 0.7 % | 0.8 % | 0.9 % |
| FCF Potential Yield (on market EV) | 7.2 % | 4.1 % | 2.3 % | 4.8 % | 3.5 % | 3.8 % | 4.1 % |
| *Adjustments made for: - | | | | | | | |


| Company Specific Items | | | | | | | |
|------------------------|---------|---------|---------|---------|---------|---------|---------|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| revenue per employee | 298.02 | 249.59 | 234.34 | 211.23 | 211.23 | 211.23 | 211.23 |
| Camera Units | 431,000 | 399,000 | 395,000 | 450,000 | 544,500 | 658,845 | 797,202 |
| Book to Bill | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| ASP | 341 | 353 | 410 | 379 | 413 | 391 | 367 |



| Consolidated profit and loss | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|
| In EUR m | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023 |
| Sales | 150.2 | 150.0 | 162.0 | 170.5 | 224.8 | 257.3 | 292.4 |
| Change Sales yoy | 54.0 % | -0.1 % | 8.0 % | 5.2 % | 31.9 % | 14.5 % | 13.6 % |
| COGS | 75.7 | 70.1 | 79.5 | 81.7 | 107.0 | 127.1 | 146.8 |
| Gross profit | 74.5 | 79.9 | 82.4 | 88.7 | 117.8 | 130.2 | 145.6 |
| Gross margin | 49.6 % | 53.3 % | 50.9 % | 52.0 % | 52.4 % | 50.6 % | 49.8 % |
| Research and development | 10.8 | 18.8 | 17.9 | 21.7 | 27.9 | 31.4 | 35.3 |
| Sales and marketing | 19.6 | 23.0 | 31.5 | 30.6 | 35.8 | 37.9 | 42.1 |
| Administration expenses | 13.1 | 12.7 | 15.8 | 17.4 | 18.2 | 19.9 | 22.1 |
| Other operating expenses | 1.2 | 1.4 | 1.0 | 0.2 | 0.9 | 1.4 | 1.6 |
| Other operating income | 0.7 | 8.0 | 0.8 | 1.1 | 0.7 | 0.6 | 0.5 |
| Unfrequent items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA | 39.7 | 36.0 | 30.0 | 34.6 | 54.9 | 60.2 | 65.5 |
| Margin | 26.4 % | 24.0 % | 18.5 % | 20.3 % | 24.4 % | 23.4 % | 22.4 % |
| Depreciation of fixed assets | 3.6 | 3.2 | 5.0 | 6.3 | 6.0 | 6.2 | 6.2 |
| EBITA | 36.1 | 32.8 | 25.0 | 28.3 | 48.9 | 54.0 | 59.3 |
| Amortisation of intangible assets | 5.6 | 7.9 | 8.0 | 8.2 | 13.3 | 13.8 | 14.3 |
| Goodwill amortisation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT | 30.5 | 24.8 | 17.0 | 20.1 | 35.7 | 40.2 | 45.0 |
| Margin | 20.3 % | 16.6 % | 10.5 % | 11.8 % | 15.9 % | 15.6 % | 15.4 % |
| EBIT adj. | 30.5 | 24.8 | 17.0 | 20.1 | 35.7 | 40.2 | 45.0 |
| Interest income | 0.3 | 0.2 | 1.0 | 1.1 | 0.2 | 0.2 | 0.2 |
| Interest expenses | 1.0 | 0.5 | 1.1 | 0.8 | 1.0 | 1.0 | 1.0 |
| Other financial income (loss) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBT | 29.8 | 24.5 | 16.9 | 20.4 | 34.9 | 39.4 | 44.2 |
| Margin | 19.8 % | 16.3 % | 10.4 % | 12.0 % | 15.5 % | 15.3 % | 15.1 % |
| Total taxes | 8.2 | 7.5 | 4.0 | 5.3 | 9.4 | 11.0 | 12.4 |
| Net income from continuing operations | 21.6 | 17.0 | 12.9 | 15.1 | 25.5 | 28.4 | 31.8 |
| Income from discontinued operations (net of tax) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income before minorities | 21.6 | 17.0 | 12.9 | 15.1 | 25.5 | 28.4 | 31.8 |
| Minority interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | 21.6 | 17.0 | 12.9 | 15.1 | 25.5 | 28.4 | 31.8 |
| Margin | 14.4 % | 11.3 % | 7.9 % | 8.9 % | 11.3 % | 11.0 % | 10.9 % |
| Number of shares, average | 9.6 | 9.6 | 9.9 | 10.0 | 10.0 | 10.0 | 10.0 |
| EPS | 2.25 | 1.76 | 1.29 | 1.51 | 2.55 | 2.84 | 3.18 |
| EPS adj. | 2.25 | 1.76 | 1.29 | 1.46 | 2.55 | 2.84 | 3.18 |
| *Adjustments made for: | | | | | | | |

Guidance: 2021 sales EUR 190-210m, EBT margin 12-14%


| Financial Ratios | | | | | | | |
|-------------------------------|---------|---------|---------|---------|---------|---------|---------|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Total Operating Costs / Sales | 29.3 % | 36.7 % | 40.4 % | 40.3 % | 36.5 % | 35.0 % | 34.4 % |
| Operating Leverage | 2.8 x | 140.8 x | -3.9 x | 3.4 x | 2.4 x | 0.9 x | 0.9 x |
| EBITDA / Interest expenses | 40.5 x | 78.2 x | 28.3 x | 45.0 x | 57.8 x | 60.2 x | 65.5 x |
| Tax rate (EBT) | 27.4 % | 30.6 % | 23.9 % | 26.0 % | 27.0 % | 28.0 % | 28.0 % |
| Dividend Payout Ratio | 30.0 % | 30.0 % | 20.1 % | 38.4 % | 30.0 % | 30.0 % | 30.0 % |
| Sales per Employee | 298,018 | 249,589 | 189,872 | 199,835 | 247,033 | 268,021 | 304,583 |





| Consolidated balance sheet | | | | | | | |
|---|-------|-------|-------|-------|-------|-------|-------|
| In EUR m | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Assets | | | | | | | |
| Goodwill and other intangible assets | 24.6 | 40.8 | 62.0 | 64.8 | 68.6 | 72.8 | 78.5 |
| thereof other intangible assets | 1.5 | 6.5 | 16.8 | 31.0 | 33.1 | 35.4 | 38.1 |
| thereof Goodwill | 3.1 | 12.7 | 27.5 | 27.5 | 27.5 | 27.5 | 27.5 |
| Property, plant and equipment | 21.3 | 22.5 | 30.6 | 29.3 | 27.8 | 26.7 | 26.4 |
| Financial assets | 1.7 | 1.7 | 4.6 | 2.2 | 2.2 | 2.2 | 2.2 |
| Other long-term assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets | 47.5 | 65.1 | 97.2 | 96.3 | 98.5 | 101.7 | 107.0 |
| Inventories | 20.8 | 21.0 | 20.9 | 20.0 | 32.1 | 36.2 | 41.2 |
| Accounts receivable | 11.1 | 18.2 | 19.4 | 19.5 | 17.9 | 21.1 | 24.0 |
| Liquid assets | 36.0 | 31.8 | 35.2 | 47.9 | 25.6 | 38.5 | 50.8 |
| Other short-term assets | 2.2 | 2.8 | 8.5 | 6.5 | 6.5 | 6.5 | 6.5 |
| Current assets | 70.2 | 73.9 | 84.0 | 93.8 | 82.0 | 102.3 | 122.5 |
| Total Assets | 117.7 | 139.0 | 181.2 | 190.1 | 180.6 | 204.0 | 229.5 |
| Liabilities and shareholders' equity | | | | | | | |
| Subscribed capital | 3.2 | 3.2 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
| Capital reserve | 3.1 | 5.3 | 22.4 | 22.6 | 22.6 | 22.6 | 22.6 |
| Retained earnings | 59.0 | 66.5 | 74.8 | 87.1 | 112.6 | 141.0 | 172.8 |
| Other equity components | 0.3 | 0.5 | -4.2 | -4.8 | -10.0 | -17.6 | -26.2 |
| Shareholders' equity | 65.6 | 75.5 | 103.0 | 114.9 | 135.2 | 155.9 | 179.2 |
| Minority interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total equity | 65.6 | 75.5 | 103.0 | 114.9 | 135.2 | 155.9 | 179.2 |
| Provisions | 7.2 | 8.3 | 8.2 | 9.4 | 10.8 | 11.1 | 11.4 |
| thereof provisions for pensions and similar obligations | 1.4 | 1.2 | 0.9 | 1.1 | 1.9 | 1.9 | 1.9 |
| Financial liabilities (total) | 29.3 | 39.8 | 50.0 | 45.1 | 13.1 | 13.1 | 13.1 |
| Short-term financial liabilities | 0.0 | 1.8 | 5.3 | 4.1 | 4.1 | 4.1 | 4.1 |
| Accounts payable | 10.1 | 7.4 | 10.6 | 11.1 | 11.7 | 14.1 | 16.0 |
| Other liabilities | 5.5 | 7.9 | 9.4 | 9.7 | 9.7 | 9.7 | 9.7 |
| Liabilities | 52.1 | 63.4 | 78.2 | 75.2 | 45.3 | 48.0 | 50.2 |
| Total liabilities and shareholders' equity | 117.7 | 139.0 | 181.2 | 190.1 | 180.6 | 204.0 | 229.5 |

| Financial Ratios | | | | | | | |
|-------------------------------------|--------|--------|--------|--------|--------|---------|---------|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Efficiency of Capital Employment | | | | | | | |
| Operating Assets Turnover | 3.5 x | 2.8 x | 2.7 x | 3.0 x | 3.4 x | 3.7 x | 3.9 x |
| Capital Employed Turnover | 2.5 x | 1.8 x | 1.4 x | 1.5 x | 1.8 x | 1.9 x | 2.0 x |
| ROA | 45.5 % | 26.1 % | 13.2 % | 15.7 % | 25.9 % | 27.9 % | 29.7 % |
| Return on Capital | | | | | | | |
| ROCE (NOPAT) | 38.4 % | 23.8 % | 12.7 % | 12.8 % | 21.9 % | 22.5 % | 23.5 % |
| ROE | 37.4 % | 24.1 % | 14.4 % | 13.9 % | 20.4 % | 19.5 % | 19.0 % |
| Adj. ROE | 37.4 % | 24.1 % | 14.4 % | 13.4 % | 20.4 % | 19.5 % | 19.0 % |
| Balance sheet quality | | | | | | | |
| Net Debt | -5.3 | 9.1 | 15.7 | -1.7 | -10.5 | -23.5 | -35.8 |
| Net Financial Debt | -6.7 | 8.0 | 14.9 | -2.8 | -12.4 | -25.4 | -37.7 |
| Net Gearing | -8.1 % | 12.1 % | 15.3 % | -1.5 % | -7.8 % | -15.1 % | -20.0 % |
| Net Fin. Debt / EBITDA | n.a. | 22.2 % | 49.6 % | n.a. | n.a. | n.a. | n.a. |
| Book Value / Share | 6.8 | 7.8 | 10.3 | 11.5 | 13.5 | 15.6 | 17.9 |
| Book value per share ex intangibles | 4.2 | 3.6 | 4.1 | 5.0 | 6.7 | 8.3 | 10.1 |




Source: Warburg Research Source: Warburg Research



| Consolidated cash flow statement | | | | | | | |
|--|------|-------|--------------|--------------|-------|--------------|--------------|
| In EUR m | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Net income | 21.6 | 17.0 | 12.9 | 15.1 | 25.5 | 28.4 | 31.8 |
| Depreciation of fixed assets | 3.6 | 3.2 | 5.0 | 6.3 | 6.0 | 6.2 | 6.2 |
| Amortisation of goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Amortisation of intangible assets | 5.6 | 7.9 | 8.0 | 8.2 | 13.3 | 13.8 | 14.3 |
| Increase/decrease in long-term provisions | 0.0 | 0.0 | -0.1 | 1.1 | 8.0 | 0.0 | 0.0 |
| Other non-cash income and expenses | 2.3 | 1.7 | -3.7 | 5.1 | 0.3 | 0.5 | 0.5 |
| Cash Flow before NWC change | 33.1 | 29.9 | 22.1 | 35.9 | 45.9 | 48.9 | 52.8 |
| Increase / decrease in inventory | -5.8 | 2.2 | 0.1 | 0.9 | -12.1 | -4.1 | - 5.0 |
| Increase / decrease in accounts receivable | -0.5 | -6.4 | -1.1 | -0.1 | 1.6 | -3.2 | - 2.9 |
| Increase / decrease in accounts payable | 5.3 | -4.5 | 3.2 | 0.5 | 0.6 | 2.4 | 1.9 |
| Increase / decrease in other working capital positions | -0.3 | 5.8 | 0.5 | 0.1 | 1.4 | 0.3 | 0.3 |
| Increase / decrease in working capital (total) | -1.3 | -2.9 | 2.7 | 1.5 | -8.4 | -4.6 | - 5.7 |
| Net cash provided by operating activities [1] | 31.8 | 27.0 | 24.7 | 37.3 | 37.5 | 44.3 | 47.2 |
| Investments in intangible assets | -4.0 | -13.6 | -29.3 | -20.6 | -17.0 | -18.0 | -20.0 |
| Investments in property, plant and equipment | -4.1 | -4.5 | - 5.1 | - 2.7 | -4.5 | - 5.1 | -5.8 |
| Payments for acquisitions | -1.9 | -7.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income from asset disposals | 0.2 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 |
| Net cash provided by investing activities [2] | -9.8 | -25.7 | -34.2 | -23.3 | -21.4 | -23.0 | -25.7 |
| Change in financial liabilities | -1.3 | 4.8 | -1.8 | 2.3 | -32.0 | 0.0 | 0.0 |
| Dividends paid | -2.4 | -6.5 | -5.1 | -2.6 | -5.8 | -7.7 | -8.5 |
| Purchase of own shares | -0.7 | -3.3 | 20.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| Capital measures | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 |
| Other | -1.1 | -0.5 | -1.0 | -0.8 | -0.6 | -0.6 | -0.6 |
| Net cash provided by financing activities [3] | -5.4 | -5.5 | 13.0 | -1.3 | -38.4 | -8.3 | -9.1 |
| Change in liquid funds [1]+[2]+[3] | 16.6 | -4.2 | 3.5 | 12.7 | -22.3 | 13.0 | 12.3 |
| Effects of exchange-rate changes on cash | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cash and cash equivalent at end of period | 36.0 | 31.8 | 35.3 | 47.9 | 25.6 | 38.5 | 50.8 |

| Financial Ratios | | | | | | | |
|--------------------------------------|---------|---------|---------|---------|---------|---------|---------|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Cash Flow | | | | | | | |
| FCF | 23.7 | 9.0 | -9.6 | 13.8 | 16.0 | 21.1 | 21.3 |
| Free Cash Flow / Sales | 15.8 % | 6.0 % | -5.9 % | 8.1 % | 7.1 % | 8.2 % | 7.3 % |
| Free Cash Flow Potential | 29.0 | 23.4 | 10.9 | 26.0 | 39.1 | 41.7 | 44.7 |
| Free Cash Flow / Net Profit | 109.5 % | 52.7 % | -74.6 % | 91.6 % | 62.6 % | 74.4 % | 66.9 % |
| Interest Received / Avg. Cash | 1.0 % | 0.5 % | 2.9 % | 2.7 % | 0.5 % | 0.6 % | 0.4 % |
| Interest Paid / Avg. Debt | 3.7 % | 1.3 % | 2.4 % | 1.6 % | 3.3 % | 7.6 % | 7.6 % |
| Management of Funds | | | | | | | |
| Investment ratio | 5.4 % | 12.0 % | 21.2 % | 13.7 % | 9.6 % | 9.0 % | 8.8 % |
| Maint. Capex / Sales | 1.9 % | 1.9 % | 3.1 % | 0.0 % | 3.0 % | 3.0 % | 3.0 % |
| Capex / Dep | 88.3 % | 161.8 % | 265.4 % | 160.6 % | 111.7 % | 115.7 % | 126.1 % |
| Avg. Working Capital / Sales | 13.5 % | 17.9 % | 19.0 % | 17.1 % | 14.8 % | 15.8 % | 15.8 % |
| Trade Debtors / Trade Creditors | 109.5 % | 246.9 % | 183.1 % | 175.9 % | 153.0 % | 149.6 % | 150.0 % |
| Inventory Turnover | 3.6 x | 3.3 x | 3.8 x | 4.1 x | 3.3 x | 3.5 x | 3.6 x |
| Receivables collection period (days) | 27 | 44 | 44 | 42 | 29 | 30 | 30 |
| Payables payment period (days) | 49 | 39 | 49 | 49 | 40 | 40 | 40 |
| Cash conversion cycle (Days) | 79 | 115 | 91 | 82 | 99 | 93 | 93 |



Source: Warburg Research Source: Warburg Research Source: Warburg Research

8



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

Basler



SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation
- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

| Company | Disclosure | Link to the historical price targets and rating changes (last 12 months) | | | | |
|---------|------------|--|--|--|--|--|
| Basier | 3, 5 | http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005102008.htm | | | | |

Rating suspended



2

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

| -B- | Buy: | The price of the analysed financial instrument is expected to rise over the next 12 months. |
|------------|-------------------|---|
| -H- | Hold: | The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months. |
| -S- | Sell: | The price of the analysed financial instrument is expected to fall over the next 12 months. |
| <u>"_"</u> | Rating suspended: | The available information currently does not permit an evaluation of the company. |

| WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING | | | | | | | |
|--|------------------|---------------|--|--|--|--|--|
| Rating | Number of stocks | % of Universe | | | | | |
| Buy | 144 | 69 | | | | | |
| Hold | 56 | 27 | | | | | |
| Sell | 5 | 2 | | | | | |

Total 210 100


5

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

| Rating | Number of stocks | % of Universe |
|------------------|------------------|---------------|
| Buy | 40 | 83 |
| Hold | 5 | 10 |
| Sell | 0 | 0 |
| Rating suspended | 3 | 6 |
| Total | 48 | 100 |

PRICE AND RATING HISTORY BASLER AS OF 07.05.2021



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



| EQUITIES | | | |
|--|--|---|---|
| Matthias Rode | +49 40 3282-2678 | | |
| Head of Equities | mrode@mmwarburg.com | | |
| RESEARCH | | | |
| Michael Heider | +49 40 309537-280 | Philipp Kaiser | +49 40 309537-260 |
| Head of Research | mheider@warburg-research.com | Real Estate | pkaiser@warburg-research.com |
| Henner Rüschmeier Head of Research | +49 40 309537-270 hrueschmeier@warburg-research.com | Thilo Kleibauer Retail, Consumer Goods | +49 40 309537-257 tkleibauer@warburg-research.com |
| Stefan Augustin | +49 40 309537-168 | Eggert Kuls | +49 40 309537-256 |
| Cap. Goods, Engineering | saugustin@warburg-research.com | Engineering | ekuls@warburg-research.com |
| Jan Bauer Renewables | +49 40 309537-155 jbauer@warburg-research.com | Andreas Pläsier Banks, Financial Services | +49 40 309537-246 aplaesier@warburg-research.com |
| Jonas Blum Telco, Media, Construction | +49 40 309537-240 jblum@warburg-research.com | Malte Schaumann Technology | +49 40 309537-170 mschaumann@warburg-research.com |
| Christian Cohrs | +49 40 309537-175 | Oliver Schwarz | +49 40 309537-250 |
| Industrials & Transportation Dr. Christian Ehmann | ccohrs@warburg-research.com +49 40 309537-167 | Chemicals, Agriculture Simon Stippig | oschwarz@warburg-research.com +49 40 309537-265 |
| BioTech, Life Science | cehmann@warburg-research.com | Real Estate | sstippig@warburg-research.com |
| Felix Ellmann Software, IT | +49 40 309537-120 fellmann@warburg-research.com | Cansu Tatar Cap. Goods, Engineering | +49 40 309537-248 ctatar@warburg-research.com |
| Jörg Philipp Frey | +49 40 309537-258 | Marc-René Tonn | +49 40 309537-259 |
| Retail, Consumer Goods | jfrey@warburg-research.com | Automobiles, Car Suppliers | mtonn@warburg-research.com |
| Marius Fuhrberg Financial Services | +49 40 309537-185 mfuhrberg@warburg-research.com | Robert-Jan van der Horst Technology | +49 40 309537-290 rvanderhorst@warburg-research.com |
| Mustafa Hidir | +49 40 309537-230 | Andreas Wolf | +49 40 309537-140 |
| Automobiles, Car Suppliers | mhidir@warburg-research.com | Software, IT | awolf@warburg-research.com |
| Ulrich Huwald Health Care, Pharma | +49 40 309537-255 uhuwald@warburg-research.com | | |
| INSTITUTIONAL EQU | | | |
| Marc Niemann | +49 40 3282-2660 | Maximilian Martin | +49 69 5050-7413 |
| Head of Equity Sales, Germany | mniemann@mmwarburg.com | Austria, Poland | mmartin@mmwarburg.com |
| Klaus Schilling | +49 40 3282-2664 | Christopher Seedorf | +49 69 5050-7414 |
| Head of Equity Sales, Germany | kschilling@mmwarburg.com | Switzerland | cseedorf@mmwarburg.com |
| Tim Beckmann United Kingdom | +49 40 3282-2665 tbeckmann@mmwarburg.com | | |
| Lea Bogdanova | +49 69 5050-7411 | | |
| United Kingdom, Ireland | lbogdanova@mmwarburg.com | | |
| Jens Buchmüller | +49 69 5050-7415 | | |
| Scandinavia, Austria Alexander Eschweiler | jbuchmueller@mmwarburg.com +49 40 3282-2669 | Sophie Hauer | +49 69 5050-7417 |
| Germany, Luxembourg | aeschweiler@mmwarburg.com | Roadshow/Marketing | shauer@mmwarburg.com |
| Matthias Fritsch | +49 40 3282-2696 | Juliane Niemann | +49 40 3282-2694 |
| United Kingdom | mfritsch@mmwarburg.com | Roadshow/Marketing | jniemann@mmwarburg.com |
| SALES TRADING | | | |
| Oliver Merckel | +49 40 3282-2634 | Marcel Magiera | +49 40 3282-2662 |
| Head of Sales Trading | omerckel@mmwarburg.com | Sales Trading | mmagiera@mmwarburg.com |
| Elyaz Dust Sales Trading | +49 40 3282-2702 edust@mmwarburg.com | Bastian Quast Sales Trading | +49 40 3282-2701 bquast@mmwarburg.com |
| Michael Ilgenstein | +49 40 3282-2700 | Jörg Treptow | +49 40 3282-2658 |
| Sales Trading | milgenstein@mmwarburg.com | Sales Trading | jtreptow@mmwarburg.com |
| MACRO RESEARCH | | | |
| Carsten Klude | +49 40 3282-2572 | Dr. Christian Jasperneite | +49 40 3282-2439 |
| Macro Research | cklude@mmwarburg.com | Investment Strategy | cjasperneite@mmwarburg.com |
| Our research can be t | | | |
| Warburg Research | research.mmwarburg.com/en/index.html | Thomson Reuters | www.thomsonreuters.com |
| Bloomberg | RESP MMWA GO | Capital IQ | www.capitaliq.com |
| FactSet | www.factset.com | | |
| For access please conta | act: | | |
| Andrea Schaper | +49 40 3282-2632 | Kerstin Muthig | +49 40 3282-2703 |
| Sales Assistance | aschaper@mmwarburg.com | Sales Assistance | kmuthig@mmwarburg.com |
| | | | |